Natco Pharma gains 4% on emergency use approval for Covid-19 medicine

Natco Pharma

Shares of Natco Pharma, on Monday, gained 4 per cent to Rs 935 on the BSE in intra-day trade after the company received emergency use approval for Baricitinib tablets for Covid-19 treatment.

In a filing, Natco Pharma said “The company has received Emergency Use approval for Baricitinib tablets, 1mg, 2mg and 4mg strengths from Central Drugs Standard Control Organization (CDSCO) in India. Baricitinib in combination with Remdesivir is used for the treatment of COVID-19 positive patients”
According to the company filing Natco will be requesting a Compulsory License from the government which is in light of the dangerous and serious public health emergency across the country due to the COVID 19 Pandemic. The company is preparing to launch the product early this week, to make the product available to patients who are suffering from COVID 19 across India, said the filing.

The previous week, Natco Pharma announced that the company had applied to the CDSCO in India for approval of Phase-III clinical trial of Molnupiravir Capsules for the treatment of COVID-19 patients.

According to Pre-clinical data, Molnupiravir has broad anti-influenza activity, including highly potent inhibition of SARS-CoV-2 replication. Patients who are treated with Molnupiravir gained response in 5 days of treatment which indicates that the time period of treatment with Molnupiravir is less. It has an additional advantage as it is consumed orally.

According to the company, it is ready to launch the product this month if approval is given.

Natco Pharma is one of the major pharmaceutical firms in India. It is located in Hyderabad. It leads to producing Hyderabad and hepatitis C drugs in India